Dr. Pray is Bernhardt Professor of Nonprescription Products and Devices at Southwestern Oklahoma State University in Weatherford, where he has taught the required course in nonprescription products for over three decades.He has been an innovator in emphasizing the role of the pharmacist in patient triage with regard to self-care decisions for minor medical conditions. Dr. Pray has published 295 articles in pharmacy, medical, and dental hygiene journals. His peer-reviewed column, “Consult Your Pharmacist” has appeared monthly in U.S. Pharmacist since 1988. He co-authored a chapter entitled "Self Care/Diagnostic Products" for the 20th Edition of Remington: The Science and Practice of Pharmacy, and was sole author of the “Self-Care” chapter for the 21stedition. Dr. Pray is a popular speaker, having presented almost 100 live and televised nonprescription product-related programs.
CARING FOR ACCIDENTS
ACPE # 043-999-10-004-L01-P
Objectives:
1. Demonstrate knowledge of the legal status and appropriate uses of ipecac and activated charcoal, complete with suggested counseling information.
2. For various strains, sprains, and backache, select an appropriate product, device, or treatment modality, and be able to provide counseling points to ensure safe patient use.
3. For various insect bites or stings, wounds, or minor burns, recognize when the injury requires triage to another medical professional, and be able to recommend appropriate therapy when self-care is indicated.
Dr. Williams is a Professor of Clinical Pharmacy and Clinical Gerontology at the University of Southern California School of Pharmacy. He is a certified geriatric pharmacist. He was the 2003 recipient of the George F. Archambault Award for contributions to senior care pharmacy, presented by the American Society of Consultant Pharmacists. He is a founding member of the Commission for Certification in Geriatric Pharmacy & serves on the Board of Directors for the ASCP. He is a member of the advisory council for the Alzheimer's Association of California.
GERIATRICS: A FOCUS ON CARDIOLOGY, GLAUCOMA, AND DEMENTIA
ACPE # 043-999-10-030-L01-P
Cardiovascular Disorders in the Elderly Objectives:
1.Identify the physiologic factors that increase the risk for cardiovascular disorders in older adults.
2.Interpret the JNC-7 Guidelines for treatment of hypertension in elderly patients.
3.Describe the role of anti-hyperlipidemics in he management of lipid disorders in older adults.
4.Discuss the risks and benefits of beta-blocker therapy in older patients with cardiovascular disease.
5.Develop a pharmacotherapeutic care plan to manage multiple cardiovascular disorders in an elderly patient.
Treatment of Glaucoma Objectives:
1.Explain the purpose and process of formation and drainage of aqueous humor.
2.Identify the primary risk factors for the development of primary open angle glaucoma.
3.Discuss the mechanisms of action of the primary medications used to treat POAG.
4.Identify the major, clinically significant, adverse effects of the above medication classes.
5.Counsel a patient regarding the proper technique for instilling eye drops.
Alzheimer's Disease Objectives:
1.Identify the typical signs and symptoms associated with Alzheimer's disease and other dementias.
2.Discuss the roles of cholinergic manipulation and NMDA inhibition in the treatment of Alzheimer's disease symptoms.
3.Recognize behavior disturbances commonly displayed by patients with dementia.
4.Develop a therapeutic strategy for treating agitated behaviors in Alzheimer's disease.
Associate Professor of Clinical Pharmacy, University of Southern California
Dr. Besinque practices in the area of outpatient community-based women's health, including emergency contraception and menopause therapies. She is a Trustee for CPhA, on the Board of Directors for the CSHP Foundation and ARHP. Her research focuses on women's health. She also is a pharmacy consultant to Planned Parenthood of Los Angeles.
WOMENS HEALTH ISSUES
ACPE # 043-999-09-040-L01-P
“Rings and Things- What’s New in Contraception”
Objectives:
Describe the mechanism of action for currently available contraceptives.
Compare the currently available contraceptives (pills, patches, rings, implants, intrauterine devices, and barriers) with respect to efficacy, side effects and safety.
Explain proper use of contraceptives to patients seeking advice from the pharmacist.
Assist men/women in the selection of a contraceptive that meets their individual needs.
Advice users and health care providers about the management of adverse effects from contraceptive formulations.
“Is there a Need to Bleed?- The Role of Extending the Hormone Cycle for Menstrual Suppression “
Objectives:
Describe the physiological changes associated with menstruation.
Discuss the common problems associated with menstruation.
Advise a woman or health care provider regarding the management of menstrual disorders including medications and non-drug therapy.
Explain the benefits of menstrual suppression to women.
Recommend pharmacological strategies for menstrual suppression.
Counsel a woman about proper use of contraceptives for extending the menstrual cycle.
“Not for Women Only- An Update on Osteoporosis”
Objectives:
Describe the physiological changes resulting in osteoporosis.
Advise patients regarding strategies to prevent osteoporosis.
Compare pharmacological agents to prevent and treat osteoporosis.
Discuss the role of Vitamin D in preventing and treating bone loss.
Caring for Accidents:Poisoning, Sprains and Strains, Insect Bites, Wounds & Burns, Geriatrics:A Focus on Cardiology, Glaucoma, and Dementia, Women's Health Issues
Stephen Setter, Pharm.D., CDE, CGP, DVM
Washington State University
Dr. Setter is an associate professor of pharmacotherapy at Washington State University. In 2004, he was recognized as a leader in Alzheimer's disease care by US Pharmacist. Currently he serves as the pharmacy consultant to the Parkinson's Resource Center, the Northwest Inland Alzheimer's Association and Elder Services in Spokane, WA. He has lectured and published extensively on geriatric pharmacy, Alzheimer's and Parkinson's disease, and managing diabetes and its complications. He has completed the Alzheimer's and Parkinson's ASCP supported traineeships and is a Fellow of ASCP.
ALZHEIMER'S & PARKINSON'S
ACPE # 043-999-08-029-L01-P
Objectives:
1. Identify the characteristics features of Alzheimer's disease
2. Recognize drugs that may complicate the treatment of Alzheimer's disease
3. Understand the pharmacological management of Alzheimer's and explore the therapeutic dilemmas and issues regarding anti-dementia pharmacotherapy
4. List the signs & symptoms of Parkinson's and identify secondary symptoms
5. Discuss the pharmacological approach to the treatment of Parkinson's disease
6. Describe the side effects commonly encountered with drugs used to treat Parkinson's and how to manage these side effects
7. Familiarize yourself with drugs that are commonly used to treat pain, dyskinesia, dementia, and psychosis in patients with Parkinson's disease
Dr. Louie received his Doctorate of Pharmacy degree from the University of California in San Francisco. He continued his basic science training at the Kuzell Institute, where he served as Associate of Research in Molecular Biology. Following his training at Kuzell, he joined the University of Southern California where he continued his work on cytokine regulation in relation to tumor and/or viral proliferation at the Kenneth Norris Cancer Research Institute. Presently, Dr. Louie is an Associate Professor at the University of Southern California School of Pharmacy and the Keck School of Medicine, where he is concentrating his work on virally-linked diseases, which include human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections. In addition, he continues his efforts in drug discovery and development for the treatment of specific brain cancers and multiple myeloma.
ADVANCES IN CANCER THERAPY
ACPE # 043-999-09-031-L01-P
Objectives:
Understand
how can emerges from normal host replication process.
Understand
how can proliferates, progress and lead to metastatic diseases.
Identify
conventional agents for various solid tumors (e.g. colon, breast, urologic
and brain cancers)
Describe
for their patients as how new kinase inhibitors are able to inhibit cancer
progression
Describe
for their patients as how new anti-angiogenesis agents would prevent the
progression of cancer proliferation
To
convey to their patients the types of adverse events that they may
encounter when receiving these types of anti-cancer agents.
To
convey to their patients methods to ameliorate some of these adverse
events that they may encounter.
Dr. Setter is an associate professor of pharmacotherapy at Washington State University. In 2004, he was recognized as a leader in Alzheimer's disease care by US Pharmacist. Currently he serves as the pharmacy consultant to the Parkinson's Resource Center, the Northwest Inland Alzheimer's Association and Elder Services in Spokane, WA. He has lectured and published extensively on geriatric pharmacy, Alzheimer's and Parkinson's disease, and managing diabetes and its complications. He has completed the Alzheimer's and Parkinson's ASCP supported traineeships and is a Fellow of ASCP.
ALZHEIMER'S & PARKINSON'S
ACPE # 043-999-08-029-L01-P
Objectives:
1. Identify the characteristics features of Alzheimer's disease
2. Recognize drugs that may complicate the treatment of Alzheimer's disease
3. Understand the pharmacological management of Alzheimer's and explore the therapeutic dilemmas and issues regarding anti-dementia pharmacotherapy
4. List the signs & symptoms of Parkinson's and identify secondary symptoms
5. Discuss the pharmacological approach to the treatment of Parkinson's disease
6. Describe the side effects commonly encountered with drugs used to treat Parkinson's and how to manage these side effects
7. Familiarize yourself with drugs that are commonly used to treat pain, dyskinesia, dementia, and psychosis in patients with Parkinson's disease
Joshua Neumiller received his doctor of pharmacy degree from Washington State University in 2005, where he is currently an assistant professor in the Department of Pharmacotherapy and a member of WSU Geriatrics Team and the WSU Clinical Trials Research Team. Dr. Neumiller is a Certified Diabetes Educator (CDE), a Certified Geriatric Pharmacist (CGP), and is a Fellow of the American Society of Consultant Pharmacists. Dr. Neumiller has published on a variety of practice- and research-based topics, and is a contributing author for the ADA book Medications for the Treatment of Diabetes. He also serves as an Associate Editor for the ADA journal Diabetes Spectrum, and is the lead pharmacist CE reviewer for the American Association of Diabetes Educators. Clinically, Dr. Neumiller is a consultant pharmacist at Elder Services, a division of Spokane Mental Health, where he provides in-home consulting services. He also serves as an investigator on multiple investigator-initiated and large multi-site clinical trials involving the study of diabetes and its complications.
NOVEMBER 12, 2010
ALZHEIMER'S & PARKINSON'S
ACPE # 043-999-08-029-L01-P
Objectives:
1. Identify the characteristics features of Alzheimer's disease
2. Recognize drugs that may complicate the treatment of Alzheimer's disease
3. Understand the pharmacological management of Alzheimer's and explore the therapeutic dilemmas and issues regarding anti-dementia pharmacotherapy
4. List the signs & symptoms of Parkinson's and identify secondary symptoms
5. Discuss the pharmacological approach to the treatment of Parkinson's disease
6. Describe the side effects commonly encountered with drugs used to treat Parkinson's and how to manage these side effects
7. Familiarize yourself with drugs that are commonly used to treat pain, dyskinesia, dementia, and psychosis in patients with Parkinson's disease
Define hypoglycemia and discuss strategies for treating hypoglycemic events.
Discuss strategies for avoiding hypoglycemic episodes in patients with diabetes mellitus.
Utilize clinical scenarios to outline common causes of hypoglycemia, and suggest appropriate interventions and/or strategies for the management of hypoglycemia.
Review the pharmacology and pharmacokinetic characteristics of currently available oral and insulin products
Recognize the therapeutic benefit of the new DPP-4 inhibitor sitagliptin
Explain the risks and benefits of exenatide and pramlintide in the treatment of diabetes
Discuss the most common insulin regimens utilized in patients with type 1 and type 2 diabetes
Utilize clinical scenarios to outline common blood glucose profiles in patients with diabetes and suggest appropriate initial oral/insulin regimens and insulin dosing adjustments to attain A1C goals
Appropriately make recommendations to incorporate new diabetes management approaches into your practice
Define diabetes mellitus (DM) and discuss the role of insulin in the treatment of DM.
Briefly review the pharmacokinetic characteristics of currently available insulin products.
Discuss the most common insulin regimens utilized in patients with type 1 and type 2 DM.
Utilize clinical scenarios to outline common blood glucose profiles in patients with DM, and suggest appropriate initial insulin regimens and insulin dosing adjustments to attain A1C goals.
Joshua Neumiller received his doctor of pharmacy degree from Washington State University in 2005, where he is currently an assistant professor in the Department of Pharmacotherapy and a member of WSU Geriatrics Team and the WSU Clinical Trials Research Team. Dr. Neumiller is a Certified Diabetes Educator (CDE), a Certified Geriatric Pharmacist (CGP), and is a Fellow of the American Society of Consultant Pharmacists. Dr. Neumiller has published on a variety of practice- and research-based topics, and is a contributing author for the ADA book Medications for the Treatment of Diabetes. He also serves as an Associate Editor for the ADA journal Diabetes Spectrum, and is the lead pharmacist CE reviewer for the American Association of Diabetes Educators. Clinically, Dr. Neumiller is a consultant pharmacist at Elder Services, a division of Spokane Mental Health, where he provides in-home consulting services. He also serves as an investigator on multiple investigator-initiated and large multi-site clinical trials involving the study of diabetes and its complications.
SATURDAY FEBRUARY 19, 2011
UPDATE on DIABETES MELLITUS for 2011: FROM NEW INSIGHTS into the PATHOPHYSIOLOGY of DIABETES to ADVANCES in TECHNOLOGY
ACPE # TBA
Objectives:
1. Review the pathophysiology of diabetes and discuss the mechanisms of action of currently available therapies.
2. Discuss currently available non-insulin therapies for the treatment of diabetes in terms of efficacy, safety, and patient-specific considerations.
3. Review currently available insulin products and delivery devices, and discuss insulin products currently in the developmental pipeline.
4. Utilize clinical scenarios to outline common blood glucose profiles in patients with diabetes, and suggest appropriate initial insulin regimens and insulin dosing adjustments to attain A1C goals.
5. Discuss clinical case scenarios to outline important counseling points for patients with diabetes.
6. Discuss care considerations for the elderly patient with type 2 diabetes mellitus.
UPDATE on the TREATMENT of MEN'S HEALTH ISSUES: A DISCUSSION from HEAD to TOE
ACPE # TBA
Objectives:
1. Review currently available drug therapies and considerations for the treatment of alopecia.
2. Discuss the symptoms and management of male hypogonadism and andropause.
3. Discuss treatment options and clinical considerations for men with benign prostatic hypertrophy (BPH).
4. Review the role of drug therapies in the treatment of prostate cancer.
5. Outline risk factors associated with erectile dysfunction and discuss the role of drug therapy in its treatment.
Update on Diabetes Mellitus for 2011; From New Insights into the Pathophysiology of Diabetes to Advances in Technology & Update on Men's Health Issues; A Discussion from Head to Toe
10
Sheraton Suites Key West newly renovated all-suite hotel across from Smather's Beach
offering complimentary shuttle to bustling Duval Street &
airport shuttle service
Renee Greaves completed her post - doctoral training in Tallahassee, FL in the area of general practice medicine with a focus in HIV. She currently practices as a Clinical Assistant Professor at Rutgers University School of Pharmacy where she precepts Pharm.D. candidates on rotation and lectures in Infectious Disease Therapeutics and a Women’s Health course elective. She also serves as the Clinical Pharmacy Coordinator at Hunterdon Medical Center with as specialty in infectious diseases and a subspecialty in critical care medicine. During the past two years, she has successfully created and maintained a general pharmacy practice residency program, established an ambulatory care program, and implemented an antibiotic stewardship program which has received national recognition by the VHA
FRIDAY MARCH 18, 2011
NEW DRUG UPDATE
ACPE # 043-999-10-003-L01-P
1. Discuss the clinical indications for the new medications approved by the FDA.
2. Explain the various mechanisms of action for the medications discussed within this program.
3.Recognize the clinically relevant drug interactions for the medications.
4. Identify the most common adverse reactions for the new drug approvals.
5. Explain the approved dosing guidelines and recommended dosage adjustments for the medications reviewed.
Dr. Louie received his Doctorate of Pharmacy degree from the University of California in San Francisco. He continued his basic science training at the Kuzell Institute, where he served as Associate of Research in Molecular Biology. Following his training at Kuzell, he joined the University of Southern California where he continued his work on cytokine regulation in relation to tumor and/or viral proliferation at the Kenneth Norris Cancer Research Institute. Presently, Dr. Louie is an Associate Professor at the University of Southern California School of Pharmacy and the Keck School of Medicine, where he is concentrating his work on virally-linked diseases, which include human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections. In addition, he continues his efforts in drug discovery and development for the treatment of specific brain cancers and multiple myeloma.
ADVANCES IN CANCER THERAPY
ACPE # 043-999-09-031-L01-P
Objectives:
1. Understand how cancer emerges from normal host replication process.
2. Understand how cancer proliferates, progress and lead to metastatic diseases.
3. Identify conventional agents for various solid tumors (e.g. colon, breast, urologic and brain cancers).
4. Describe how new kinase inhibitors are able to inhibit cancer progression.
5. Describe how new anti-angiogenesis agents would prevent the progression of cancer proliferation.
6. Describe the types of adverse events that a patient may encounter when receiving these types of anti-cancer agents.
7. Describe methods to ameliorate some of these adverse events.
Dr. Long is a professor of Pharmacology and Toxicology at the College of Pharmacy at Southwestern Oklahoma State University. His areas of interest, research, and expertise include the pharmacognosy, pharmacology, and toxicology of natural products; veterinary medicine; toxicology of agrichemicals and pesticides; and substance misuse, abuse and addiction; as well as general pharmacology. He has published basic research papers in each of these areas as well as contributing chapters to Comprehensive Pharmacy Review and the Professional's Handbook of Complimentary and Alternative Medicines.
HERBAL PRODUCTS AND ALTERNATIVE THERAPIES
ACPE # 043-999-09-037-L01-P
Objectives:
1. Review scientific and clinical data to assess the potential benefit and/or harm that alternative therapies present.
2. Assess the benefits and risks to a patient's health in recommending alternative therapies.
3. Demonstrate knowledge of the most commonly used herbal products.
New Drug Update, Advances in Cancer Therapy, Herbal Products and Alternative Therapies
15
Harrah's New Orleans AAA Four-Diamond Award Winning Hotel & Casino
located at the French Quarter
Dr. Williams is a Professor of Clinical Pharmacy and Clinical Gerontology at the University of Southern California School of Pharmacy. He is a certified geriatric pharmacist. He was the 2003 recipient of the George F. Archambault Award for contributions to senior care pharmacy, presented by the American Society of Consultant Pharmacists. He is a founding member of the Commission for Certification in Geriatric Pharmacy & serves on the Board of Directors for the ASCP. He is a member of the advisory council for the Alzheimer's Association of California.
GERIATRICS: EVALUATING THE OLDER PATIENT, TREATING INCONTINENCE, AND MANAGING GI DISORDERS
Tools to Evaluate the Geriatric Patient Objectives:
1.Describe the characteristics of a successful interview to obtain and record pertinent health information while maintaining patient confidentiality.
2.Recognize medications that are potentially inappropriate for older adults and list therapeutic alternatives.
3.Identify assessment instruments that allow the pharmacist to identify potential health problems in older adults and discuss their use in monitoring pharmacotherapy.
4.Identify the components of a pharmaceutical care plan that is specific for elderly clients.
5.Identify patient outcomes that can be achieved through providing pharmaceutical care services to older adults.
Treatment of Incontinence Objectives:
1.Define urge, stress, overflow and functional incontinence.
2.Describe the etiology and pathophysiology of each type of incontinence.
3.Explain the mechanism of action of the primary medications used in each type of incontinence.
4.List two common adverse effects for each of the primary therapies.
5.Describe the typical signs and symptoms of benign prostatic hyperplasia (BPH).
6. Explain the mechanisms of action for the primary drug therapies employed for the treatment of BPH.
Managing GI Disorders Objectives:
1.Identify factors that predispose older adults to gastrointestinal disorders such as chronic constipation, gastroesophageal reflux disease, and peptic ulcer disease.
2.Describe the common presenting signs and symptoms of gastrointestinal disorders in the elderly.
3.Design a non-pharmacological treatment strategy for older adults who suffer from gastroesophageal reflux disease or constipation.
4.Compare and contrast the available pharmacotherapeutic options for the treatment of common gastrointestinal disorders in the elderly.
GERIATRICS III: A FOCUS ON PARKINSON"S DISEASE AND OSTEOPOROSIS
ACPE #
Treating Parkinson's Disease Objectives:
1. Describe the clinical features and pathophysiology of Parkinson's disease, essential tremor, and choreiform disorders.
2. Compare and contrast drug therapies used in the treatment of Parkinson's disease.
3. Describe the long-term complications of Parkinson's disease and discuss effective management strategies.
4. Discuss the pharmacological treatment options for essential tremor.
5. Discuss the benefits and risks associated with the pharmacotherapeutic options for the treatment of chorea in older adults.
Osteoporosis Objectives:
1. Discuss the pathogenesis and clinical presentation of osteoporosis in postmenopausal women.
2. Determine the requirements for calcium and vitamin D supplementation in the prevention of osteoporosis.
3. Evaluate the risks and benefits of products available for the prevention and treatment of osteoporosis, including estrogen, calcitonin, biphosphonates, and parathyroid hormone.
4. Develop a treatment plan for a postmenopausal woman with osteoporosis.
Geriatrics: Evaluating The Older Patient, Incontinence, and Managing GI Disorders; Geriatrics: A Focus on Cardiology, Glaucoma, and Dementias; Parkinsons's Disease and Osteoporosis
15
Dreams Punta Cana Resort & Spa Voted Best Family Resort-Caribbean & Best Pool Caribbean by Trip Advisor Traveler's Choice. Recognized by Preferred Hotels & Resorts Worldwide. Includes room, all meals & snacks, alcoholic & non-alcoholic beverages, and entertainment
$154 per person per night double occupancy
$219 per person per night single occupancy
PASSPORTS REQUIRED
Dr. Benefield is a clinical assistant professor of pharmacy at the University of Texas at Austin. He has practiced in the areas of developmental disabilities, hospice and long term care for the last 16 years. He has authored & co- authored chapters in Pharmacotherapy and Applied Therapeutics. He has been a lecturer at the national meetings of the ACCP, ASCP, American Epilepsy Society, American Academy of Neurology, and NCDEU.
REFRACTORY DEPRESSION and UNDERSTANDING THE CYTOCHROME P450 SYSTEM
ACPE # 043-999-10-007-L01-P
Objectives:
1. Critically evaluate tolerability and efficacy data pertaining to long-term pharmacotherapy for major depressive disorder.
2. Discuss novel strategies and delivery mechanisms for pharmacologic agents used in the management of depression.
3. Define treatment-resistant depression.
4. Identify the various treatment options when first-line interventions do not result in adequate clinical improvement.
5. Delineate appropriate interventions for treatment resistant depression.
6. List the major mechanisms responsible for drug metabolism.
7. Describe the major enzyme systems in the body that are responsible for oxidation, reduction and/or hydrolysis of selective pharmacological agents.
8. Describe the basic principles of how drug metabolism alters drug action.
9. Explain how drugs are chemically altered by cytochrome p-450.
10 Explain how drug-induced enzyme induction and inhibition can alter responses to drugs.
11. Discuss the basic clinical interactions that can result from changes in drug metabolism during co-administration of drugs.
Dr. Setter is an associate professor of pharmacotherapy at Washington State University. In 2004, he was recognized as a leader in Alzheimer's disease care by US Pharmacist. Currently he serves as the pharmacy consultant to the Parkinson's Resource Center, the Northwest Inland Alzheimer's Association and Elder Services in Spokane, WA. He has lectured and published extensively on geriatric pharmacy, Alzheimer's and Parkinson's disease, and managing diabetes and its complications. He has completed the Alzheimer's and Parkinson's ASCP supported traineeships and is a Fellow of ASCP.
RHEUMATOID and OSTEOARTHRITIS
ACPE # 043-999-09-015-L01-P
Objectives:
•Identify the distinguishing characteristics of osteoarthritis (OA)
•List and discuss the risk factors for developing OA
•List the medications commonly used to treat OA as well as their potential advantages, contraindications, and side effects
•Discuss the risk factors for developing NSAID-induced GI ulcerationand cardiorenal side effects
•Formulate a comprehensive therapeutic plan for the patient with OA
•Define rheumatoid arthritis
•List and understand the terms used to describe the extra-articular manifestations of RA
•Explain some of the unique laboratory tests performed for patients with RA
•Discuss why the pyramid is falling
•Discuss the monitoring parameters for the anti-rheumatic drugs discussed
•List the drugs used to treat RA
•Evaluate a drug regimen and make appropriate recommendations for the patient with rheumatoid arthritis
Dr. Terriff has provided clinical pharmacy services to Internal Medicine and Critical Care medical teams at Deaconess Medical Center over the past 12 years. She provides pharmaceutical care to HIV/AIDS patients in an outpatient clinic. Shefounded a post-graduate pharmacy residency in infectious disease. Dr. Terriff teaches a multitude of topics in required and elective infectious disease courses to pharmacy students .
INFECTIOUS DISEASES: AN UPDATE IN THE TREATMENT OF HIV AND HEPATITIS
ACPE # TBA
Objectives:
Refractory Depression & Understanding the Cytochrome P450 System, Arthritis, Infectious Diseases: An Update in the Treatment of HIV and Hepatitis
Dr. Steven Chen is an Associate Professor at the University of Southern California School of Pharmacy. His current clinical practice role includes the provision of clinical and consultative services to three safety net community clinics surrounding the university and USC Family Medicine, where he precepts Level IV pharmacy students and postgraduate pharmacy residents. Dr. Chen's lecture topics for the school of pharmacy include asthma and chronic obstructive pulmonary disease, arthritis, dyslipidemia, and other cardiovascular diseases.
SATUR
ASTHMA
ACPE # 043-999-08-042-L01-P
Objectives:
1. Discuss the similarities and differences between the 2007 NHLBI asthma treatment guidelines and the 2002 guideline update in regards to the evaluation, treatment, and monitoring of asthma patients.
2. Interview an asthma patient to determine level of asthma control.
3. Explain strategies for controlling common environmental triggers of asthma.
4. Describe strategies for minimizing the use of rescue medications, including short-acting beta2 agonists.
5. Describe a strategy for addressing asthma patients who appear to be resistant to inhaled corticosteroid therapy.
6. List common asthma-related treatment problems that can be identified and resolved through outpatient pharmacies.
7. Explain the proper use of common asthma-related devices.
Dr. Steven Chen is an Associate Professor at the University of Southern California School of Pharmacy. His current clinical practice role includes the provision of clinical and consultative services to three safety net community clinics surrounding the university and USC Family Medicine, where he precepts Level IV pharmacy students and postgraduate pharmacy residents. Dr. Chen's lecture topics for the school of pharmacy include asthma and chronic obstructive pulmonary disease, arthritis, dyslipidemia, and other cardiovascular diseases.
ASTHMA
ACPE # 043-999-08-042-L01-P
Objectives:
1. Discuss the similarities and differences between the 2007 NHLBI asthma treatment guidelines and the 2002 guideline update in regards to the evaluation, treatment, and monitoring of asthma patients.
2. Interview an asthma patient to determine level of asthma control.
3. Explain strategies for controlling common environmental triggers of asthma.
4. Describe strategies for minimizing the use of rescue medications, including short-acting beta2 agonists.
5. Describe a strategy for addressing asthma patients who appear to be resistant to inhaled corticosteroid therapy.
6. List common asthma-related treatment problems that can be identified and resolved through outpatient pharmacies.
7. Explain the proper use of common asthma-related devices.
Renee Greaves completed her post - doctoral training in Tallahassee, FL in the area of general practice medicine with a focus in HIV. She currently practices as a Clinical Assistant Professor at Rutgers University School of Pharmacy where she precepts Pharm.D. candidates on rotation and lectures in Infectious Disease Therapeutics and a Women’s Health course elective. She also serves as the Clinical Pharmacy Coordinator at Hunterdon Medical Center with as specialty in infectious diseases and a subspecialty in critical care medicine. During the past two years, she has successfully created and maintained a general pharmacy practice residency program, established an ambulatory care program, and implemented an antibiotic stewardship program which has received national recognition by the VHA
FRIDAY JULY 8, 2011
NEW DRUG UPDATE
ACPE # 043-999-10-003-L01-P
1. Discuss the clinical indications for the new medications approved by the FDA.
2. Explain the various mechanisms of action for the medications discussed within this program.
3.Recognize the clinically relevant drug interactions for the medications.
4. Identify the most common adverse reactions for the new drug approvals.
5. Explain the approved dosing guidelines and recommended dosage adjustments for the medications reviewed.
Dr. Pray is Bernhardt Professor of Nonprescription Products and Devices at Southwestern Oklahoma State University in Weatherford, where he has taught the required course in nonprescription products for over three decades.He has been an innovator in emphasizing the role of the pharmacist in patient triage with regard to self-care decisions for minor medical conditions. Dr. Pray has published 295 articles in pharmacy, medical, and dental hygiene journals. His peer-reviewed column, “Consult Your Pharmacist” has appeared monthly in U.S. Pharmacist since 1988. He co-authored a chapter entitled "Self Care/Diagnostic Products" for the 20th Edition of Remington: The Science and Practice of Pharmacy, and was sole author of the “Self-Care” chapter for the 21stedition. Dr. Pray is a popular speaker, having presented almost 100 live and televised nonprescription product-related programs.
SATURDAY JULY 9, 2011
CONSULT YOUR PHARMACIST: SELF-IMPROVEMENT PRODUCTS
ACPE # TBA
Objectives:
1. Demonstrate knowledge of the causes and/or symptoms of weight loss, nicotine cessation, hair loss or removal, fatigue, sleep disorders, hemorrhoids, and foot care.
2. Select an appropriate product, device, or treatment modality and be able to provide counseling points to ensure safe patient use.
3. Recognize when the condition requires triage to another medical professional and be able to recommend appropriate therapy when self-care is indicated.
1. Demonstrate knowledge of the legal status and appropriate uses of ipecac and activated charcoal, complete with suggested counseling information.
2. For various strains, sprains, and backache, select an appropriate product, device, or treatment modality, and be able to provide counseling points to ensure safe patient use.
3. For various insect bites or stings, wounds, or minor burns, recognize when the injury requires triage to another medical professional, and be able to recommend appropriate therapy when self-care is indicated.
Joshua Neumiller received his doctor of pharmacy degree from Washington State University in 2005, where he is currently an assistant professor in the Department of Pharmacotherapy and a member of WSU Geriatrics Team and the WSU Clinical Trials Research Team. Dr. Neumiller is a Certified Diabetes Educator (CDE), a Certified Geriatric Pharmacist (CGP), and is a Fellow of the American Society of Consultant Pharmacists. Dr. Neumiller has published on a variety of practice- and research-based topics, and is a contributing author for the ADA book Medications for the Treatment of Diabetes. He also serves as an Associate Editor for the ADA journal Diabetes Spectrum, and is the lead pharmacist CE reviewer for the American Association of Diabetes Educators. Clinically, Dr. Neumiller is a consultant pharmacist at Elder Services, a division of Spokane Mental Health, where he provides in-home consulting services. He also serves as an investigator on multiple investigator-initiated and large multi-site clinical trials involving the study of diabetes and its complications.
SATURDAY AUGUST 6, 2011
UPDATE on DIABETES MELLITUS for 2011: FROM NEW INSIGHTS into the PATHOPHYSIOLOGY of DIABETES to ADVANCES in TECHNOLOGY
ACPE # TBA
Objectives:
1. Review the pathophysiology of diabetes and discuss the mechanisms of action of currently available therapies.
2. Discuss currently available non-insulin therapies for the treatment of diabetes in terms of efficacy, safety, and patient-specific considerations.
3. Review currently available insulin products and delivery devices, and discuss insulin products currently in the developmental pipeline.
4. Utilize clinical scenarios to outline common blood glucose profiles in patients with diabetes, and suggest appropriate initial insulin regimens and insulin dosing adjustments to attain A1C goals.
5. Discuss clinical case scenarios to outline important counseling points for patients with diabetes.
6. Discuss care considerations for the elderly patient with type 2 diabetes mellitus.
Joshua Neumiller received his doctor of pharmacy degree from Washington State University in 2005, where he is currently an assistant professor in the Department of Pharmacotherapy and a member of WSU Geriatrics Team and the WSU Clinical Trials Research Team. Dr. Neumiller is a Certified Diabetes Educator (CDE), a Certified Geriatric Pharmacist (CGP), and is a Fellow of the American Society of Consultant Pharmacists. Dr. Neumiller has published on a variety of practice- and research-based topics, and is a contributing author for the ADA book Medications for the Treatment of Diabetes. He also serves as an Associate Editor for the ADA journal Diabetes Spectrum, and is the lead pharmacist CE reviewer for the American Association of Diabetes Educators. Clinically, Dr. Neumiller is a consultant pharmacist at Elder Services, a division of Spokane Mental Health, where he provides in-home consulting services. He also serves as an investigator on multiple investigator-initiated and large multi-site clinical trials involving the study of diabetes and its complications.
SATURDAY AUGUST 6, 2011
UPDATE on DIABETES MELLITUS for 2011: FROM NEW INSIGHTS into the PATHOPHYSIOLOGY of DIABETES to ADVANCES in TECHNOLOGY
ACPE # TBA
Objectives:
1. Review the pathophysiology of diabetes and discuss the mechanisms of action of currently available therapies.
2. Discuss currently available non-insulin therapies for the treatment of diabetes in terms of efficacy, safety, and patient-specific considerations.
3. Review currently available insulin products and delivery devices, and discuss insulin products currently in the developmental pipeline.
4. Utilize clinical scenarios to outline common blood glucose profiles in patients with diabetes, and suggest appropriate initial insulin regimens and insulin dosing adjustments to attain A1C goals.
5. Discuss clinical case scenarios to outline important counseling points for patients with diabetes.
6. Discuss care considerations for the elderly patient with type 2 diabetes mellitus.
Dr. Holmquist is on the Board of Advisors of the American Society of Pain Educators. Over the past decade, he has been invited to present over 1,000 CME and CE lectures on pain management across the country. He shares practical and relevant clinical information, with a touch of humor, ensuring that audiences not only listen but also hear an important message on managing pain and making a difference in the lives of their patients.
MANAGING PAIN & SYMPTOMS IN THE END-OF-LIFE PATIENT
ACPE # 043-999-09-038-L01-P
Objectives:
1. State the current philosophy of hospice & palliative care in the United States
2. State 5 barriers to providing effective end-of-life care
3. Understand the principles on intended / unintended consequences and double effect and how these may apply to managing pain and other symptoms at end-of-life
4. Differentiate nociceptive, visceral and neuropathic pain
5. Differentiate addiction, dependence, tolerance, pseudoaddiction, pseudotolerance, and hyperalgesia
6. Compare the ability to titrate opioid doses to obtain effective analgesia and convert between opioids with equianalgesic doses and maintain analgesia
7. Compare and contrast the pharmacology, pharmacokinetics, side effects, and clinical utilization of the commercially available opioid products
8. State the advantages and disadvantages of the following routes for delivering pain medications: oral, rectal, transdermal, sublingual/buccal, subcutaneous, intravenous, spinal
9. State the common side effects associated with pain medications and be able to recommend strategies to prevent the side effects from impacting the patient's quality of life
10. State the role of selected co-analgesic and adjuvant pain therapies in the management of pain
11. State the general management of end of life symptoms such as breathlessness, pruritus, anorexia, edema, depression, anxiety, insomnia, delirium and myoclonus.
Dr. Steven Chen is an Associate Professor at the University of Southern California School of Pharmacy. His current clinical practice role includes the provision of clinical and consultative services to three safety net community clinics surrounding the university and USC Family Medicine, where he precepts Level IV pharmacy students and postgraduate pharmacy residents. Dr. Chen's lecture topics for the school of pharmacy include asthma and chronic obstructive pulmonary disease, arthritis, dyslipidemia, and other cardiovascular diseases.
HYPERTENSION and DYSLIPIDEMIA
ACPE # 043-999-09-013-L01-P
Objectives:
1. Describe the proper method of blood pressure measurement.
2. Identify nonpharmacologic interventions that can reduce blood pressure.
3. Initiate or recommend a patient-specific antihypertensive drug therapy regimen, considering demographics, medical history, and other important variables.
4. List major barriers to successful hypertension control.
5. Discuss the relative value of lipoprotein parameters and other tests for establishing cardiovascular risk and treatment goals.
6. Develop an evidence-based treatment plan for managing patients with dyslipidemia, accounting for significant comorbid conditions (i.e. diabetes, secondary prevention).
7. Explain the role of lipid-modifying agents in light of recent major recommendations, guidelines, and clinical trials.
8. Identify strategies for reducing the risk of major adverse events associated with lipid-modifying medications.
Associate Professor of Clinical Pharmacy, University of Southern California
Dr. Besinque practices in the area of outpatient community-based women's health, including emergency contraception and menopause therapies. She is a Trustee for CPhA, on the Board of Directors for the CSHP Foundation and ARHP. Her research focuses on women's health. She also is a pharmacy consultant to Planned Parenthood of Los Angeles.
HPV, EMERGENCY CONTRACEPTION, and NUTRITIONAL SUPPORT FOR WOMEN
ACPE # TBA
Managing Pain and Symptoms in the End-of-Life Patient, Hypertension & Dyslipidemia, HPV, Emergency Contraception, and Nutritional Support for Women
Dr. Holmquist is on the Board of Advisors of the American Society of Pain Educators. Over the past decade, he has been invited to present over 1,000 CME and CE lectures on pain management across the country. He shares practical and relevant clinical information, with a touch of humor, ensuring that audiences not only listen but also hear an important message on managing pain and making a difference in the lives of their patients.
MANAGING PAIN & SYMPTOMS IN THE END-OF-LIFE PATIENT
ACPE # 043-999-09-038-L01-P
Objectives:
1. State the current philosophy of hospice & palliative care in the United States
2. State 5 barriers to providing effective end-of-life care
3. Understand the principles on intended / unintended consequences and double effect and how these may apply to managing pain and other symptoms at end-of-life
4. Differentiate nociceptive, visceral and neuropathic pain
5. Differentiate addiction, dependence, tolerance, pseudoaddiction, pseudotolerance, and hyperalgesia
6. Compare the ability to titrate opioid doses to obtain effective analgesia and convert between opioids with equianalgesic doses and maintain analgesia
7. Compare and contrast the pharmacology, pharmacokinetics, side effects, and clinical utilization of the commercially available opioid products
8. State the advantages and disadvantages of the following routes for delivering pain medications: oral, rectal, transdermal, sublingual/buccal, subcutaneous, intravenous, spinal
9. State the common side effects associated with pain medications and be able to recommend strategies to prevent the side effects from impacting the patient's quality of life
10. State the role of selected co-analgesic and adjuvant pain therapies in the management of pain
11. State the general management of end of life symptoms such as breathlessness, pruritus, anorexia, edema, depression, anxiety, insomnia, delirium and myoclonus.
Managing Pain and Symptoms in the End-of Life Patient
Dr. Benefield is a clinical assistant professor of pharmacy at the University of Texas at Austin. He has practiced in the areas of developmental disabilities, hospice and long term care for the last 16 years. He has authored & co- authored chapters in Pharmacotherapy and Applied Therapeutics. He has been a lecturer at the national meetings of the ACCP, ASCP, American Epilepsy Society, American Academy of Neurology, and NCDEU.
ANXIETY DISORDERS
ACPE # 043-999-09-006-L01-P
Objectives:
1. Review the clinical presentation of generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder and social phobia/social anxiety disorder.
2. Identify the common comorbidities that may complicate recognition and management for each disorder.
3. Discuss evidence-based approaches to manage the symptoms of each disorder.
4. Strategize treatment via review of patient case studies.
Dr. Stuart Haines is a professor in the Department of Pharmacy Practice at the University of Maryland School of Pharmacy. He is past-president of the ACCP and is currently a member of the ASHP Commission on Credentialing-the body that sets standards and accredits pharmacy residency and technician training programs in the United States. He is a Board Certified Pharmacotherapy Specialist and Board Certified in Advanced Diabetes Management. in 2006, Dr. Haines was elected Distinguished Practitioner in the National Academies of Practice.
THYROID DISEASE and ANTICOAGULTION THERAPY
ACPE # 043-999-09-035-L01-P and 043-999-09-036-L01-P
Objectives:
1. Recognize symptoms and signs consistent with hypothyroidism and thyrotoxicosis.
2. State the therapeutic objectives for primary hypothyroidism, Graves disease, and subacute thyroiditis.
3. Compare and contrast drug treatment for each disease.
4. Develop an appropriate treatment plan, including drug and non-drug therapies.
5. Develop a monitoring plan and a patient educational plan for each.
6. Identify potential drug-drug interactions.
Objectives for Anticoagulation:
1. Recommend an appropriate antithrombotic regimen given a patient at high risk for venous thromboembolism.
2. Recommend an appropriate monitoring plan including baseline laboratory tests given a patient receiving antithrombotic therapy.
3. Given a case involving a patient who is excessively anticoagulated, recommend an appropriate course of action including pharmacological and non-pharmacological interventions, monitoring parameters, and antithrombotic therapy management.
4. Identify the contraindications for the use of antithrombotic drugs.
5. Identify drug-drug and drug-food interactions.
6. Explain why warfarin requires 7 to 14 days to achieve its full anticoagulation effect.
7. List the major sites for bleeding related to anticoagulation therapy.
8. Given the patient's prothrombin time, the laboratory's control PT, and the ISI of the reagent used, calculate the INR.
9. List the major adverse effects related to antithrombotic therapy other than bleeding; explain the probable mechanism of each; recommend a strategy to avoid or treat each.
10. Given a patient on warfarin or unfractionated heparin, recommend an appropriate therapeutic goal in terms of laboratory monitoring parameters.
Dr. Virgil Van Dusen is a professor of pharmaceutical sciences in the College of Pharmacy at Southwestern Oklahoma State University in Weatherford. He has authored numerous articles dealing with legal and management issues related to pharmacy practice and has a special interest in legal concerns for pharmacy education. Dr. Van Dusen is a nationally recognized consultant in pharmacy law.
Dr. Holmquist is on the Board of Advisors of the American Society of Pain Educators. Over the past decade, he has been invited to present over 1,000 CME and CE lectures on pain management across the country. He shares practical and relevant clinical information, with a touch of humor, ensuring that audiences not only listen but also hear an important message on managing pain and making a difference in the lives of their patients.
MANAGING PAIN & SYMPTOMS IN THE END-OF-LIFE PATIENT
ACPE # 043-999-09-038-L01-P
Objectives:
1. State the current philosophy of hospice & palliative care in the United States
2. State 5 barriers to providing effective end-of-life care
3. Understand the principles on intended / unintended consequences and double effect and how these may apply to managing pain and other symptoms at end-of-life
4. Differentiate nociceptive, visceral and neuropathic pain
5. Differentiate addiction, dependence, tolerance, pseudoaddiction, pseudotolerance, and hyperalgesia
6. Compare the ability to titrate opioid doses to obtain effective analgesia and convert between opioids with equianalgesic doses and maintain analgesia
7. Compare and contrast the pharmacology, pharmacokinetics, side effects, and clinical utilization of the commercially available opioid products
8. State the advantages and disadvantages of the following routes for delivering pain medications: oral, rectal, transdermal, sublingual/buccal, subcutaneous, intravenous, spinal
9. State the common side effects associated with pain medications and be able to recommend strategies to prevent the side effects from impacting the patient's quality of life
10. State the role of selected co-analgesic and adjuvant pain therapies in the management of pain
11. State the general management of end of life symptoms such as breathlessness, pruritus, anorexia, edema, depression, anxiety, insomnia, delirium and myoclonus.
Managing Pain and Symptoms in the End-of-Life Patient
Dr. Wincor is an Associate Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences at the University of Southern
California Schools of Pharmacy and Medicine; in addition he is Director of Continuing Pharmacy Education and International
Programs for the School of Pharmacy. Dr. Wincor received his B.S. in Zoology from the University of Chicago, where he was actively
involved in sleep research, and his Pharm.D. and Residency Certificate in Psychiatric Pharmacy Practice from USC. He is affiliated
with the American Academy of Sleep Medicine and the Sleep Research Society. He has been named Professor of the Year seven
of the last eight years at the University of Southern California.
THURSDAY NOVEMBER 10, 2011
DRUGS USED IN PSYCHIATRY: AN UPDATE
ACPE # TBA
Objectives:
1. Utilize the mental status exam and similar assessment tools for monitoring a patient's response to psychotherapeutic agents.
2. Demonstrate knowledge of the indications for the use of the general categories of psychotropic medications.
3. Recognize the usual therapeutic dosage ranges for the various psychotropic agents.
4. Recognize the common and serious side effects for the general classes of psychotropic agents.
5. List the major precautions and contraindications associated with the general classes of psychotropic medications.
6. Describe the symptomatology one would expect to alter by using the various psychotropic agents in the treatment of specific disorders, as well as the expected time course of these changes.
ADVANCES IN THE TREATMENT OF INSOMNIA AND OTHER SLEEP DISORDERS
ACPE # TBA
Objectives:
1. Describe the normal architecture of sleep and the changes seen with aging.
2. Identify factors contributing to excessive daytime sleepiness and insomnia and recommend appropriate pharmacological and nonpharmacological treatment treatment options.
3. Describe the advantages and limitations of the currently used classes of hypnotic agents.
4. Compare the BZD1-receptor specific nonbenzodiazepines with each other and with other benzodiazepine agonists.
5. Evaluate the mechanism of action, pharmacokinetic profile, clinical efficacy, and safety of controlled-release zolpidem and ramelteon relative to other available hypnotics.
When calling a hotel or cruise-line for reservations, be sure to mention Getaway Seminars for special group rates. Seminar agenda and pricing available on the About Us page
